CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report

CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Detalles Bibliográficos
Autores principales: Urbantat, Ruth M., Popper, Valentin, Menschel, Elisabeth, Pfeilstöcker, Michael, Forjan, Ernst, Nader, Alexander, Sieghart, Catherine R., Keil, Felix, Koller, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077323/
https://www.ncbi.nlm.nih.gov/pubmed/33936618
http://dx.doi.org/10.1002/ccr3.3909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077323/
https://www.ncbi.nlm.nih.gov/pubmed/33936618
http://dx.doi.org/10.1002/ccr3.3909

Ejemplares similares